Tysabri Brain Infection Risk
Risk of Brain Infection With Multiple Sclerosis Drug Tysabri. The risk of developing a potentially fatal brain infection is higher than previously thought for patients taking the genetically engineered multiple sclerosis drug Tysabri (natalizumab), scientists reported this week. Tysabri, made by Biogen, is prescribed for patients … [Read more...] about Tysabri Brain Infection Risk
Tysabri PML Risk Increases With Use
Tysabri PML Risk Increases. Tysabri, a popular treatment for relapsing multiple sclerosis (MS), is more likely to cause a serious brain infection called progressive multifocal leukoencephalopathy, or PML, the longer it is used, according to the U.S. Food & Drug Administration (FDA). The agency announced Friday that the … [Read more...] about Tysabri PML Risk Increases With Use
Biogen Idec Restarts Tysabri Updates
Biogen Restarts Tysabri Update. The maker of Tysabri will once again provide monthly updates regarding new cases of progressive multifocal leukoencephalopathy, or PML, an often fatal brain infection seen in some people treated with the multiple sclerosis (MS) drug. Biogen Idec Inc. had stopped providing the monthly PML updates last … [Read more...] about Biogen Idec Restarts Tysabri Updates
Tysabri Scrutiny Over Brain Infection
Tysabri May Cause Brain Infection. European regulators are taking another look at Tysabri. According to The Wall Street Journal, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is concerned that Tysabri may have a higher rate of a rare brain infection called progressive multifocal … [Read more...] about Tysabri Scrutiny Over Brain Infection
Tysabri-PML Link Will Weigh on Biogen Stock
Tysabri-PML Link Drag Biogen Stock. Tysabri troubles could continue to cause a drag on Biogen Idec stock, according to a Wall Street Journal report. A recently released research note from Barclays Capital indicated use of Tysabri is being tempered by worries over how many patients may develop progressive multifocal … [Read more...] about Tysabri-PML Link Will Weigh on Biogen Stock
Tysabri Safety Info Includes PML Cases
Tysabri Safety Info. The Food & Drug Administration (FDA) is updating Tysabri safety information to include cases of progressive multifocal leukoencephalopathy or PML, a rare brain infection that some Tysabri patients have developed. However, according to The Wall Street Journal, the agency is not making any changes to … [Read more...] about Tysabri Safety Info Includes PML Cases
Brain Infection in More Tysabri Patients
Tysabri Patients Brain Infection Reported. Two more Tysabri patients have developed progressive multifocal leukoencephalopathy or PML. Both new cases occurred in European patients, according to a Wall Street Journal report. Tysabri was taken off the market in 2005 in the U.S. after three patients in clinical trials … [Read more...] about Brain Infection in More Tysabri Patients
10th Tysabri Patient Stricken with PML
Tysabri Patient Stricken with PML. Another Tysabri patient has developed progressive multifocal leukoencephalopathy or PML. This brings the total number of cases of the brain infection linked to Tysabri since it was reintroduced to market to 10. Of those patients, at least 3 have died. According to a report in the Boston Business … [Read more...] about 10th Tysabri Patient Stricken with PML
Tysabri Linked to Another Case of PML
Tysabri Linked to PML. Another Tysabri patient has developed progressive multifocal leukoencephalopathy (PML), an often fatal brain disease. Just three months ago, Biogen Idec said two additional patients had contracted PML. PML attacks the brain and central nervous system and is usually fatal. It is caused by a polyomavirus, … [Read more...] about Tysabri Linked to Another Case of PML
Tysabri Labeling Changes Sought by European Regulators
Tysabri Labeling Changes. The European Medicines Agency wants to raise awareness of a deadly brain infection associated with the drug Tysabri. It recommended Thursday that the product information for Tysabri (natalizumab) be updated to include more information about the risk of progressive multifocal leukoencephalopathy … [Read more...] about Tysabri Labeling Changes Sought by European Regulators
Tysabri PML Cases Get Attention of European Drug Agency
Tysabri PML Cases Get Attention. European health regulators are taking a hard look at two cases of a potentially lethal brain infection linked to the drug Tysabri. About 31,800 people take Tysabri, which is also used to treat Multiple Sclerosis and Crohn’s disease, a digestive condition. Earlier this month, Elan and Biogen Idec, … [Read more...] about Tysabri PML Cases Get Attention of European Drug Agency
Tysabri Now Linked to Severe Liver Damage
Tysabri Linked to Severe Liver Damage. Tysabri, a controversial drug used to treat Multiple Sclerosis (MS) manufactured by Biogen Idec Inc. and Elan Corp. has been linked to serious liver damage. This liver failure can occur within six days of the first dose of Tysabri. Tysabri, which was removed from the market in 2005 … [Read more...] about Tysabri Now Linked to Severe Liver Damage
Tysabri Waltzes through FDA Advisory Panel by 12-0
Tysabri Were Suspended Due To A Fatal Side Effects. When sales of Tysabri were suspended on February 28, 2005, many critics of the highly controversial MS drug, with potentially fatal side-effects, hoped that would end the saga of a medication that many experts believed should never have been approved in the first place. That, … [Read more...] about Tysabri Waltzes through FDA Advisory Panel by 12-0
Colorado widower sues Elan and Biogen
Elan and Biogen Are Being Sued. The widower of a woman who died from a rare brain disease after participating in a clinical trial of Biogen Idec's multiple sclerosis drug Tysabri yesterday sued the Cambridge company and its partner, Elan Pharmaceuticals of Ireland. The wrongful death suit, filed in Middlesex Superior Court by … [Read more...] about Colorado widower sues Elan and Biogen
Biogen, Elan Sued For Allegedly Concealing MS Drug Risks
Risks Of MS Drug Tysabri. A patient is suing Biogen Idec and Elan Corp. PLC, accusing them of concealing risks of their multiple-sclerosis drug Tysabri before withdrawing it from the market. Bloomberg News reported that the patient filed a federal court suit in San Francisco claiming both companies knew the drug could … [Read more...] about Biogen, Elan Sued For Allegedly Concealing MS Drug Risks
TYSABRI: THE DRUG THAT REFUSES TO DIE
TYSABRI Linked To Fatal Brain Disease. Despite the fact that Tysabri has been linked to five cases of a rare and often fatal brain disease, its manufacturers (Elan Corp. PLC of Ireland and Biogen Idec Inc. of Massachusetts) are simply unwilling to give up their quest to bring the drug to market and keep it … [Read more...] about TYSABRI: THE DRUG THAT REFUSES TO DIE
Biogen, Elan hit with lawsuit over Tysabri
Lawsuit Against The Maker Of Tysabri. The family of a woman who died in February after participating in a clinical trial of multiple-sclerosis medications has filed a lawsuit against the manufacturers of the drugs. The woman's family has sued Biogen Idec Inc. of Cambridge, Mass., and Elan Pharmaceuticals of San … [Read more...] about Biogen, Elan hit with lawsuit over Tysabri
MULTIPLE SCLEROSIS DRUG (TYSABRI) RESPONSIBLE FOR BRAIN DISEASE
Multiple Sclerosis Drug Tysabri May Cause Rare Brain Disease. Yesterday, we reported that the FDA had been informed by Biogen Idec Inc. that a fourth person may have died from a rare and often fatal brain disease known as progressive multifocal leukoencephalopathy (PML). embattled multiple sclerosis MS drug After short-term … [Read more...] about MULTIPLE SCLEROSIS DRUG (TYSABRI) RESPONSIBLE FOR BRAIN DISEASE
MS DRUG (TYSABRI) RESPONSIBLE FOR RARE BRAIN DISEASE
MS Drug Tysabri May Cause Rare Brain Disease. The FDA has been informed by Biogen Idec Inc. That a fourth person may now have died from a rare brain disease known as progressive multifocal leukoencephalopathy (PML). deaths from PML which had led to the suspension of the drug After being treated with its multiple … [Read more...] about MS DRUG (TYSABRI) RESPONSIBLE FOR RARE BRAIN DISEASE
